General Thyroid Cancer

Low-Dose Radioiodine Effective in Thyroid Cancer (05-10-2012)

Low-dose radioiodine is as effective as high-dose in the treatment of thyroid cancer, according to the results of two separate studies published in the New England Journal of Medicine. The results mean that radiation doses could be cut to one-third of... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (03-26-2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Cabozantinib Shows Benefit in Medullary Thyroid Cancer (10-28-2011)

In a Phase III clinical trial, the investigational drug cabozantinib significantly delayed the progression of advanced medullary thyroid cancer. Detailed results are expected to be presented at an upcoming medical conference. Medullary thyroid cancers... Continue Reading

Use of Radioactive Iodine for Thyroid Cancer Has Increased (08-29-2011)

Use of radioactive iodine for the treatment of well-differentiated thyroid cancer has increased over time in the United States, even among patients who have an excellent prognosis with surgery alone. These results were published in the Journal of the... Continue Reading

Stay on Top of Your Family History of Cancer (07-15-2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Fosbretabulin Tromethamine in Addition to Chemotherapy may Improve Survival in Advanced Thyroid Cancer (06-9-2011)

The addition of fosbretabulin tromethamine (CA4P) to standard chemotherapy significantly improved survival at one year compared to chemotherapy alone in advanced anaplastic thyroid cancer. These results were recently presented at the 2011 annual meeting... Continue Reading

Vandetanib Approved for Medullary Thyroid Cancer (04-12-2011)

The US Food and Drug Administration (FDA) has approved vandetanib for the treatment of adult patients with metastatic, medullary thyroid cancer that is growing or causing symptoms and cannot be treated surgically. Medullary thyroid cancers account for... Continue Reading

Votrient Promising in Advanced Differentiated Thyroid Cancer (11-1-2010)

Votrient® (pazopanib) appears highly active against advanced, radioiodine-refractory differentiated thyroid cancer. These results were presented at the 14th International Thyroid Congress. The thyroid is a gland in the throat that produces hormones mostly... Continue Reading

High Prevalence of CAM Use Among Thyroid Cancer Patients (11-1-2010)

Among patients with thyroid cancer, use of complementary and alternative medicine is common, with more than 80% reporting use. These results were presented at the 14th International Thyroid Congress. Complementary and alternative medicines are therapies... Continue Reading

Vandetanib Delays Progression of Advanced Medullary Thyroid Cancer (07-16-2010)

Results of a Phase III clinical trial indicate that the investigational drug vandetanib delays the progression of locally advanced or metastatic medullary thyroid cancer. These results were presented at the 2010 annual meeting of the American Society... Continue Reading

« Previous PageNext Page »